GW Pharmaceuticals PLC's stock spiked at 811p on Sept. 26 – its highest value this year on the London Stock Exchange – following the publication of the third set of positive Phase III data this year for its cannabinoid Epidiolex (cannabidiol) in rare forms of pediatric epilepsy.
The most recent data from a second Phase III study in in patients with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy, showed that those treated with Epidiolex 20 mg/kg/day achieved a median reduction in monthly drop seizures (ie, those that make people fall) of 42% compared with a reduction of 17% in patients taking placebo (p=0.0047)
